Apitegromab is a monoclonal antibody commercialized by Scholar Rock Holding, with a leading Phase III program in Spinal Muscular Atrophy (SMA). According to Globaldata, it is involved in 7 clinical trials, of which 3 were completed, 3 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Apitegromab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Apitegromab is expected to reach an annual total of $322 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Apitegromab Overview
Apitegromab (SRK-015) is under development for the treatment of type 2 and type 3 spinal muscular atrophy (SMA) and obesity. It is administered through Intravenous route. The drug candidate is a niche modulator inhibiting activation of the latent myostatin precursor. It was under development for the treatment of Becker muscular dystrophy and other muscle wasting disorders (additional myostatin related disorders).
Scholar Rock Holding Overview
Scholar Rock Holding (Scholar Rock) is a late-stage biopharmaceutical company that discovers, develops and delivers innovative medicines for the treatment of serious diseases. The company’s pipeline products include apitegromab, a human monoclonal antibody that inhibits myostatin activation that targets spinal muscular atrophy; SRK-439, an investigational myostatin inhibitor that treats cardiometabolic disorders; SRK-181, an inhibitor of the activation of latent transforming growth factor beta for cancers treatment; and potent and selective inhibitors of the activation of TGFß for the treatment of fibrotic diseases. The company has collaborated with Gilead Sciences Inc to discover and develop specific inhibitors. Scholar Rock is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$171.3 million in FY2023, compared to an operating loss of US$134.4 million in FY2022. The net loss of the company was US$165.8 million in FY2023, compared to a net loss of US$134.5 million in FY2022.
For a complete picture of Apitegromab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
